Evidence map›Paper›PMID 39851114›Full record

ArticleCurrent medicinal chemistry2026

Oridonin Suppresses the Malignant Progression of Lung Cancer by Targeting S100A11.

Yulin Luo, Jingjing Li, Yao Chen, Yan Huang, Qi Luo, Qiang Luo, Qingqing Huang, Gang Huang, Mingming Jin

Abstract read
PubMed Publisher
In one paragraph

Article in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yulin LuoShanghai University of Traditional Chinese Medicine, Shanghai, 201203, P.R. China.
Jingjing LiShanghai University of Traditional Chinese Medicine, Shanghai, 201203, P.R. China.
Yao ChenShanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai, 201318, China.
Yan HuangShanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai, 201318, China.
Qi LuoShanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai, 201318, China.
Qiang LuoShanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai, 201318, China.
Qingqing HuangShanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai, 201318, China.
Gang HuangShanghai University of Traditional Chinese Medicine, Shanghai, 201203, P.R. China.
Mingming JinShanghai University of Traditional Chinese Medicine, Shanghai, 201203, P.R. China.

Funding

Construction project of Shanghai Key Laboratory of Molecular Imaging 18DZ2260400Key Program of National Natural Science Foundation of China 81830052
6 · The paper itself

Abstract

backgroundLung cancer (LC) is the second most lethal cancer and efficient treatments are missing. Our understanding of the underlying pathogenic mechanisms remains limited. Oridonin is a compound extracted from the Chinese herb Rabdosia rubescens with anticancer properties. Nevertheless, its effects on LC and the underlying mechanisms remain unknown.

methodsIn the current research, A549 and Hcc1833 cells were treated with different doses of oridonin, and cell proliferation and migration were detected using CCK8, EdU, Transwell, and wound healing assays. A subcutaneous tumor and caudal vein metastasis model was generated to verify the inhibitory effects of oridonin on Hcc1833 tumor growth and metastasis in vivo. Proteomics analyses then were performed to examine the regulatory mechanism. LiP-SMap combined with microscale thermophoresis and molecular docking analyses were used to validate the relationship between oridonin and S100A11.

resultsData showed that oridonin suppressed cell proliferation and migration depending on dose and suppressed tumor growth and invasion. LiP-SMap and molecular docking analyses confirmed that oridonin interacted with the Asn-53 residue of S100A11, which inhibited the activation of oridonin. S100A11 overexpression reversed the inhibitory effects of oridonin on cell proliferation and migration.

conclusionIn conclusion, the data indicate that oridonin suppresses LC malignant progression by targeting S100A11.

Indexed as

Antineoplastic AgentsAntineoplastic Agents, PhytogenicDiterpenes, KauraneLung NeoplasmsAnimalsCell Line, TumorCell MovementCell ProliferationDisease ProgressionDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansMiceMice, Inbred BALB CMolecular Docking SimulationStructure-Activity RelationshipAntineoplastic AgentsAntineoplastic Agents, PhytogenicDiterpenes, Kauraneoridoninlung cancermalignant progressionmicroscale thermophoresismolecular docking.OridoninmS100A11

Identifiers

PMID39851114

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.